Putting a stop to nonsense: Revisiting gene correction therapy for neurofibromatosis type 1

Putting a stop to nonsense: Revisiting gene correction therapy for neurofibromatosis type 1

Bibliographic Details
Main Author:	David H. Gutmann
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Series:	Molecular Therapy: Nucleic Acids
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253123002214

Similar Items

Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1
by: Sara H. Osum, et al.
Published: (2023-09-01)

Stop that nonsense!
by: Catherine L Jopling
Published: (2014-09-01)

Neurofibromatosis type 1 in childhood /
by: 385112 North, Kathryn, et al.
Published: (1997)

RAS and beyond: the many faces of the neurofibromatosis type 1 protein
by: Corina Anastasaki, et al.
Published: (2022-02-01)

Stop the illusory nonsense! Teaching transformative delict
by: Emile Zitzke
Published: (2014-08-01)

Stop the illusory nonsense! Teaching transformative delict
by: Emile Zitzke
Published: (2014-08-01)

Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma
by: Cora Antoinette Ricker, et al.
Published: (2016-12-01)

A Conserved Circadian Function for the Neurofibromatosis 1 Gene
by: Lei Bai, et al.
Published: (2018-03-01)

Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects
by: Tang Y, et al.
Published: (2023-07-01)

Severe Untreated Scoliosis and Early Onset Breast Cancer in a Patient with Neurofibromatosis Associated with a Nonsense Variant of NF1 Gene
by: Reinhold V, et al.
Published: (2023-09-01)

SCN5A Nonsense Mutation and NF1 Frameshift Mutation in a Family With Brugada Syndrome and Neurofibromatosis
by: Emanuele Micaglio, et al.
Published: (2019-02-01)

Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1
by: Buono FD, et al.
Published: (2019-08-01)

Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
by: Claudia Santoro, et al.
Published: (2018-03-01)

Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic
by: Francesca Logiacco, et al.
Published: (2023-03-01)

Commentary: Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I
by: Corina Anastasaki, et al.
Published: (2019-03-01)

Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle
by: Karen K. Norton, et al.
Published: (1995-02-01)

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
by: Prabhakar, Shilpa, et al.
Published: (2022)

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
by: Shilpa Prabhakar, et al.
Published: (2022-09-01)

Mosaic neurofibromatosis type 1 or segmental neurofibromatosis: what is in the name?
by: Kakar Shruti, et al.
Published: (2022-01-01)

Neurofibromatosis type 1, from gene mutation to clinical presentation
by: N. Dukuze, et al.
Published: (2023-06-01)

Extended stop codon context predicts nonsense codon readthrough efficiency in human cells
by: Kotchaphorn Mangkalaphiban, et al.
Published: (2024-03-01)

Dangerous Stops: Nonsense Mutations Can Dramatically Increase Frequency of Prion Conversion
by: Alexander A. Dergalev, et al.
Published: (2021-02-01)

Cranio-orbital-temporal neurofibromatosis: An uncommon subtype of neurofibromatosis type-1
by: Nibedita Acharya, et al.
Published: (2014-01-01)

Conserved Nonsense-Prone CpG Sites in Apoptosis-Regulatory Genes: Conditional Stop Signs on the Road to Cell Death
by: Yongzhong Zhao, et al.
Published: (2013-07-01)

Conserved Nonsense-Prone CpG Sites in Apoptosis-Regulatory Genes: Conditional Stop Signs on the Road to cell Death
by: Yongzhong Zhao, et al.
Published: (2013-01-01)

A CASE OF NEUROFIBROMATOSIS TYPE 1
by: Valentina Dimitrova, et al.
Published: (2008-10-01)

Endocrinological Evaluations of a Neurofibromatosis Type 1 Cohort: Is it Necessary to Evaluate Autoimmune Thyroiditis in Neurofibromatosis Type 1?
by: Serhat Güler, et al.
Published: (2017-12-01)

Ocular gamut of neurofibromatosis type 1
by: Prathibha Shanthaveerappa, et al.
Published: (2023-01-01)

Pulsating Enophthalmos in Neurofibromatosis Type 1
by: Yildiray Yildirim, et al.
Published: (2015-12-01)

Cutaneous Findings in Neurofibromatosis Type 1
by: Bengisu Ozarslan, et al.
Published: (2021-01-01)

Clinical Masks of Neurofibromatosis Type 1
by: R. N. Mustafin
Published: (2022-03-01)

Neurofibromatosis type 1 and cardiac manifestations
by: Faruk İncecik, et al.
Published: (2015-12-01)

Becker′s nevus with neurofibromatosis type 1
by: Sumit Kar, et al.
Published: (2015-01-01)

Type 1 neurofibromatosis with periodontal manifestations
by: Pramod Kumar, et al.
Published: (2016-01-01)

Bone Manifestations of Neurofibromatosis Type 1
by: Ibrahima Dokal Diallo, et al.
Published: (2022-05-01)

Constipation in adults with neurofibromatosis type 1
by: Cecilie Ejerskov, et al.
Published: (2017-08-01)

Neurofibromatosis type 1: Surgical Perspectives
by: Nthumba PM, MMed(Surg),FCS(ECSA), Plastic Surgery Fellowship, et al.
Published: (2011-07-01)

Lisch spots in neurofibromatosis type 1
by: Saxena Rajesh, et al.
Published: (1991-01-01)

Adrenal incidentaloma in neurofibromatosis type 1
by: Tančić-Gajić Milina, et al.
Published: (2008-01-01)

Statins, bone, and neurofibromatosis type 1
by: Korf Bruce R
Published: (2008-07-01)